X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1324) 1324
Publication (87) 87
Patent (86) 86
Conference Proceeding (27) 27
Book Review (10) 10
Magazine Article (8) 8
Dissertation (7) 7
Newspaper Article (5) 5
Book / eBook (3) 3
Book Chapter (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (368) 368
female (226) 226
male (220) 220
middle aged (201) 201
aged (169) 169
index medicus (157) 157
adult (137) 137
rheumatology (119) 119
oncology (114) 114
lung cancer (86) 86
respiratory system (83) 83
chemotherapy (67) 67
cancer (57) 57
life sciences (52) 52
treatment outcome (50) 50
lung neoplasms - pathology (46) 46
aged, 80 and over (45) 45
prognosis (45) 45
animals (43) 43
prospective studies (42) 42
lung neoplasms - drug therapy (41) 41
mutation (39) 39
osteoarthritis (38) 38
humanities and social sciences (36) 36
carcinoma, non-small-cell lung - drug therapy (35) 35
follow-up studies (34) 34
lung neoplasms - genetics (32) 32
radiography (32) 32
chemistry (31) 31
retrospective studies (31) 31
hematology, oncology and palliative medicine (30) 30
neoplasm staging (30) 30
carcinoma, non-small-cell lung - pathology (29) 29
care and treatment (29) 29
chemistry, organic (29) 29
therapy (29) 29
chemistry, inorganic & nuclear (27) 27
lung cancer, non-small cell (27) 27
lung neoplasms - mortality (27) 27
biological anthropology (26) 26
disease-free survival (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (25) 25
disease progression (25) 25
expression (25) 25
medicine, general & internal (25) 25
analysis (24) 24
immunotherapy (24) 24
risk factors (24) 24
patients (23) 23
tumors (23) 23
blasting (22) 22
carcinoma, non-small-cell lung - genetics (22) 22
docetaxel (22) 22
genetics (22) 22
heating (22) 22
lighting (22) 22
mechanical engineering (22) 22
survival (22) 22
weapons (22) 22
knee (21) 21
performing operations (21) 21
transporting (21) 21
adenocarcinoma (20) 20
combined heating and refrigeration systems (20) 20
heat pump systems (20) 20
liquefaction solidification of gases (20) 20
liquefaction, solidification or separation of gases or gaseous (20) 20
manufacture or storage of ice (20) 20
mixtures by pressure and cold treatment (20) 20
refrigeration or cooling (20) 20
research (20) 20
time factors (20) 20
apoptosis (19) 19
carcinoma, non-small-cell lung - mortality (19) 19
epidemiology (19) 19
lung neoplasms - therapy (19) 19
nivolumab (19) 19
[ shs.anthro-bio ] humanities and social sciences/biological anthropology (18) 18
[shs.anthro-bio]humanities and social sciences/biological anthropology (18) 18
adolescent (18) 18
biomarkers (18) 18
france (18) 18
general tagging of cross-sectional technologies spanning over several sections of the ipc (18) 18
general tagging of new technological developments (18) 18
medicine & public health (18) 18
metastasis (18) 18
open-label (18) 18
surgery (18) 18
technical subjects covered by former uspc (18) 18
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (18) 18
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (18) 18
tomography, x-ray computed (18) 18
arthritis (17) 17
biochemistry & molecular biology (17) 17
carcinoma (17) 17
hip (17) 17
internal medicine (17) 17
management (17) 17
vehicles in general (17) 17
classification (16) 16
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 7, pp. 629 - 640
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2015, Volume 26, Issue 5, pp. 908 - 914
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 5, pp. 894 - 901
Background: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population.... 
KRAS | MEK inhibitor | NSCLC | Progression-free survival | Trametinib | Docetaxel | SURVIVAL | CRITERIA | EFFICACY | progression-free survival | BEHAVIOR | ADENOCARCINOMAS | trametinib | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | ONCOGENE | MEK INHIBITION | ONCOLOGY | docetaxel | MUTATIONS | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Taxoids - therapeutic use | Time Factors | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Signal Transduction - drug effects | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Biomarkers, Tumor - genetics | Pyridones - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Pyridones - adverse effects | Original
Journal Article
1962, 108., Volume 108., 5
Book
by Ramalingam, S and Crawford, J and Chang, A and Manegold, C and Perez-Soler, R and Douillard, J.-Y and Thatcher, N and Barlesi, F and Owonikoko, T and Wang, Y and Pultar, P and Zhu, J and Malik, R and Malik Giaccone, R and Della-Fiorentina, S and Begbie, S and Jennens, R and Dass, J and Pittman, K and Ivanova, N and Koynova, T and Petrov, P and Tomova, A and Tzekova, V and Couture, F and Hirsh, V and Burkes, R and Sangha, R and Ambrus, M and Janaskova, T and Musil, J and Novotny, J and Zatloukal, P and Jakesova, J and Klenha, K and Roubec, J and Vanasek, J and Fayette, J and Barlesi, F and Bennouna-Louridi, J and Chouaid, C and Mazières, J and Vallerand, H and Robinet, G and Souquet, P.-J and Spaeth, D and Schott, R and Lena, H and Martinet, Y and Kouri, C.E and Baize, N and Scherpereel, A and Molinier, O and Fuchs, F and Josten, K.M and Manegold, C and Marschner, N and Schneller, F and Overbeck, T and Thomas, M and von Pawel, J and Reck Schuette, M and Hagen, V and Schneider, C.-P and Georgoulias, V and Varthalitis, I and Zarogoulidis, K and Syrigos, K and Papandreou, C and Bocskei, C and Csanky, E and Juhasz, E and Losonczy, G and Mark, Z and Molnar, I and Papai-Szekely, Z and Tehenes, S and Vinkler, I and Almel, S and Bakshi, A and Bondarde, S and Maru, A and Pathak, A and Pedapenki, R.M and Prasad, K and Prasad, S.V.S.S and Kilara, N and Gorijavolu, D and Deshmukh, C.D and John, S and Sharma, L.M and Amoroso, D and Bajetta, E and Bidoli, P and Bonetti, A and De Marinis, F and Maio, M and Passalacqua, R and Cascinu, S and Bearz, A and ... and FORTIS-M Study Investigators and on behalf of the FORTIS-M Study Investigators
Annals of Oncology, ISSN 0923-7534, 11/2013, Volume 24, Issue 11, pp. 2875 - 2880
Journal Article
Nature, ISSN 0028-0836, 08/2012, Volume 488, Issue 7411, pp. 370 - 374
Journal Article